Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Appili Therapeutics Inc T.APLI

Alternate Symbol(s):  APLIF

Healthcare
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSX:APLI)

Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.

GlobeNewswire 3 days ago

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025

GlobeNewswire 8 days ago

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Business Wire November 8, 2024

Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Business Wire November 7, 2024

Appili Therapeutics Announces Results of Special Meeting of Shareholders

GlobeNewswire November 6, 2024

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem

Business Wire November 6, 2024

The top TSX healthcare stocks under $1

Jonathon Brown November 5, 2024

Aditxt's Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Business Wire October 31, 2024

Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

GlobeNewswire October 31, 2024
View More News ››

Opinion & Analysis (TSX:APLI)

No current opinion is available.
View More Opinion ››

Bullboard Posts (TSX:APLI)

RE:New shareholder.

I'm curious. Do you still think this one will gain value in the near future?
MrBinks - August 18, 2024

Appili Therapeutics Sign Definitive Agreement to be Acquired

Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced...
Betteryear2 - April 2, 2024

ATI -1701

Appili was granted a pre-IND meeting with the FDA to discuss ATI-1701’s regulatory, CMC, toxicology, and Phase 1 strategies and expects...
BradlTheGerman - December 17, 2023

New shareholder.

I have bought my first 75.000 shares over the last two weeks. I am going to double or triple my position over the next year. I will hold...
BradlTheGerman - December 16, 2023

FDA approval for ATI-1501

Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ(TM) (ATI-1501) Metronidazole Oral Suspension Very important milestone...
mba123ccu - September 25, 2023

Seems severely under-valued. Big potential

This stock looks to have been severely punished in the past and perhaps folks are starting to look at their pipeline and realize that it&...
RJSullivan - July 17, 2023
View more Bullboard ››

Theralase Technologies Inc.

Theralase Technologies Inc.

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research ...
View More »